Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

August 30, 2026

Study Completion Date

December 31, 2026

Conditions
Multiple Sclerosis
Interventions
DRUG

Cladribine

All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI

Trial Locations (2)

66212

College Park Family Care Center Physicians Group, Overland Park

75390

UT Southwestern Medical center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT04178005 - Cladribine Tablets After Treatment With Natalizumab (CLADRINA) | Biotech Hunter | Biotech Hunter